Resistance to BCMA-targeted therapies in MM can arise through various mechanisms, broadly classified into three categories: (i) tumor-intrinsic, (ii) tumor microenvironment-related, and (iii) host-related (Figure 1 and Figure 2) [23]. Here, TNFRSF17 is linked to Miyoshi myopathy.